- Business Wire•3 hours agoOpdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032
Bristol-Myers Squibb Company announced today updated results for Opdivo monotherapy and in combination with Yervoy in previously treated small cell lung cancer patients, a cohort of the Phase 1/2 open-label CheckMate -032 trial.
- Business Wire•17 hours agoSeattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS in combination with Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||55.62 x 1100|
|Ask||55.63 x 2300|
|Day's Range||55.56 - 55.95|
|52 Week Range||49.03 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.88|
|Dividend & Yield||1.52 (2.72%)|
|1y Target Est||N/A|